Phase 4
Completed N=90
Bone Marrow Aspirate Compared to Platelet Rich Plasma for Treating Knee Osteoarthritis
Source: ClinicalTrials.gov NCT03289416 ↗Enrolled (actual)
90
Serious AEs
2.2%
Results posted
Apr 2025
Primary outcomePrimary: Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Measurements — 32.1; 35.3; 19.5; 19.8 score on a scale
◆ Published Evidence
Established
85citations · ~14 / year
Bone Marrow Aspirate Concentrate Is Equivalent to Platelet-Rich Plasma for the Treatment of Knee Osteoarthritis at 1 Year: A Prospective, Randomized Trial.
Summary
This study is intended to compare whether bone marrow aspirate concentrate or platelet rich plasma injections is more effective in treating knee osteoarthritis.
Linked Publications (2)
-
Bone Marrow Aspirate Concentrate Is Equivalent to Platelet-Rich Plasma for the Treatment of Knee Osteoarthritis at 1 Year: A Prospective, Randomized Trial.
-
Bone Marrow Aspirate Concentrate Is Equivalent to Platelet-Rich Plasma for the Treatment of Knee Osteoarthritis at 2 Years: A Prospective Randomized Trial.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Measurements |
32.1; 35.3; 19.5; 19.8; 18.2; 15.2 | — |
| SECONDARY Subjective International Knee Documentation Committee Subjective Score (IKDC) |
47.4; .909; 58.4; 58.5; 61.6; 63.6 | — |
Eligibility Criteria
Inclusion Criteria
- Male or female age 18-80 years
- Knee osteoarthritis
- Subjects must present with pain or swelling to target knee for at least 4 months
- Kellgren-Lawrence score between 1 and 3 upon x-ray evaluation
- Must be willing and able to provide informed consent
- Willing and able to return for scheduled follow-up visits
Exclusion Criteria
- Major mechanical axis deviation of more than 50% into either compartment (varus or valgus )
- Have had a corticosteroid injection within 3 months or a hyaluronic acid injection within 6 months
- History of the following medical conditions:
- diabetes
- autoimmune disorders
- disorders requiring immunosuppression
- rheumatoid arthritis
- hemophilic arthropathy
- infectious arthritis
- Charcot's knee
- Paget's disease of the femur or tibia
- Cancer
- Ongoing infectious disease
- Significant cardiovascular, renal or hepatic disease
Data sourced from ClinicalTrials.gov (NCT03289416) and the linked publication. Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.